Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells

DNMT inhibitors are promising new drugs for cancer therapies. In this study, we have observed the antileukemic action of two diverse DNMT inhibitors, the nucleoside agent zebularine and the non-nucleoside agent RG108, in human promyelocytic leukemia (PML) HL-60 cells. Zebularine but not RG108 caused...

Descripción completa

Detalles Bibliográficos
Autores principales: Savickiene, Jurate, Treigyte, Grazina, Borutinskaite, Veronika-Viktorija, Navakauskiene, Ruta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SP Versita 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275587/
https://www.ncbi.nlm.nih.gov/pubmed/22820861
http://dx.doi.org/10.2478/s11658-012-0024-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275587/
https://www.ncbi.nlm.nih.gov/pubmed/22820861
http://dx.doi.org/10.2478/s11658-012-0024-5

Ejemplares similares